Fractyl Health, Inc. (NASDAQ:GUTS) Director Acquires $20,322.54 in Stock

Fractyl Health, Inc. (NASDAQ:GUTS) Director William Bradley purchased 16,129 shares of the stock in a transaction dated Thursday, March 13th. The stock was acquired at an average price of $1.26 per share, for a total transaction of $20,322.54. Following the completion of the transaction, the director now directly owns 16,129 shares of the company’s stock, valued at approximately $20,322.54. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Fractyl Health Stock Up 2.4 %

GUTS stock opened at $1.26 on Thursday. The company’s 50 day simple moving average is $1.62 and its 200-day simple moving average is $2.14. The firm has a market capitalization of $61.64 million and a PE ratio of -0.10. Fractyl Health, Inc. has a 12 month low of $1.16 and a 12 month high of $8.37. The company has a debt-to-equity ratio of 0.60, a current ratio of 5.58 and a quick ratio of 5.57.

Fractyl Health (NASDAQ:GUTS) last released its quarterly earnings results on Monday, March 3rd. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.08). Equities analysts expect that Fractyl Health, Inc. will post -1.61 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Morgan Stanley lowered their price target on shares of Fractyl Health from $18.00 to $10.00 and set an “overweight” rating on the stock in a research report on Monday, February 3rd.

Institutional Trading of Fractyl Health

A number of hedge funds have recently bought and sold shares of GUTS. Massachusetts Financial Services Co. MA boosted its position in Fractyl Health by 4.9% during the third quarter. Massachusetts Financial Services Co. MA now owns 1,045,672 shares of the company’s stock worth $2,646,000 after acquiring an additional 49,289 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its position in Fractyl Health by 56.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 80,664 shares of the company’s stock worth $204,000 after acquiring an additional 29,262 shares during the last quarter. BNP Paribas Financial Markets boosted its position in Fractyl Health by 54.1% during the third quarter. BNP Paribas Financial Markets now owns 21,072 shares of the company’s stock worth $53,000 after acquiring an additional 7,397 shares during the last quarter. HighTower Advisors LLC acquired a new stake in Fractyl Health during the third quarter worth approximately $38,000. Finally, State Street Corp boosted its holdings in shares of Fractyl Health by 129.4% in the 3rd quarter. State Street Corp now owns 113,415 shares of the company’s stock valued at $287,000 after purchasing an additional 63,968 shares during the last quarter.

Fractyl Health Company Profile

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.